Dashboard
Manage Tickers

EXELEXELIXIS, INC.

Nasdaq exelixis.com


$ 27.50 $ 1.01 (3.82 %)    

Monday, 16-Sep-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.14 $ -2.10 (-0.44 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ 27.47
$ 26.72
$ 27.48 x 400
-- x --
$ 26.57 - $ 27.50
$ 18.64 - $ 27.53
1,993,793
na
7.84B
$ 0.66
$ 22.39
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-28-2024 10-Q
2 04-30-2024 03-29-2024 10-Q
3 02-06-2024 12-29-2023 10-K
4 11-01-2023 09-29-2023 10-Q
5 08-01-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 02-07-2023 12-30-2022 10-K
8 11-01-2022 09-30-2022 10-Q
9 08-09-2022 07-01-2022 10-Q
10 05-10-2022 04-01-2022 10-Q
11 02-18-2022 12-31-2021 10-K
12 11-02-2021 10-01-2021 10-Q
13 08-05-2021 07-02-2021 10-Q
14 05-06-2021 04-02-2021 10-Q
15 02-11-2021 01-01-2021 10-K
16 11-05-2020 10-02-2020 10-Q
17 08-06-2020 07-03-2020 10-Q
18 05-05-2020 04-03-2020 10-Q
19 02-25-2020 01-03-2020 10-K
20 10-30-2019 09-27-2019 10-Q
21 07-31-2019 06-28-2019 10-Q
22 05-01-2019 03-29-2019 10-Q
23 02-22-2019 12-28-2018 10-K
24 11-01-2018 09-28-2018 10-Q
25 08-01-2018 06-29-2018 10-Q
26 05-02-2018 03-30-2018 10-Q
27 02-26-2018 12-29-2017 10-K
28 11-01-2017 09-29-2017 10-Q
29 08-02-2017 06-30-2017 10-Q
30 05-01-2017 03-31-2017 10-Q
31 02-27-2017 12-30-2016 10-K
32 11-03-2016 09-30-2016 10-Q
33 08-03-2016 07-01-2016 10-Q
34 05-04-2016 04-01-2016 10-Q
35 02-29-2016 01-01-2016 10-K
36 11-10-2015 10-02-2015 10-Q
37 08-11-2015 07-03-2015 10-Q
38 04-30-2015 04-03-2015 10-Q
39 03-02-2015 12-31-2014 10-K
40 11-04-2014 09-26-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

exelixis-announces-final-results-from-phase-3-pivotal-cabinet-study-evaluating-cabozantinib-in-advanced-neuroendocrine-tumors-presented-at-esmo-2024-and-published-in-new-england-journal-of-medicine
Exelixis Announces Final Results From Phas...
09/16/2024 12:47:52

– Cabozantinib continues to demonstrate a significant improvement in progression-free survival versus placebo in patients with ...

reported-sunday-exelixis-presents-final-phase-3-contact-02-survival-data-for-cabozantinib-combo-in-metastatic-prostate-cancer-at-esmo-2024
Reported Sunday, Exelixis Presents Final P...
09/16/2024 07:19:18

Exelixis, Inc. (NASDAQ:EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal st...

expert-outlook-exelixis-through-the-eyes-of-5-analysts
Expert Outlook: Exelixis Through The Eyes ...
08/08/2024 19:06:37

truist-securities-reiterates-buy-on-exelixis-raises-price-target-to-33
Truist Securities Reiterates Buy on Exelix...
08/08/2024 12:36:14

Truist Securities analyst Asthika Goonewardene reiterates Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from...

jmp-securities-maintains-market-outperform-on-exelixis-raises-price-target-to-29
JMP Securities Maintains Market Outperform...
08/07/2024 20:32:12

JMP Securities analyst Silvan Tuerkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and raises the price target...

analyst-sees-exelixis-at-inflection-point-despite-mixed-trial-results
Analyst Sees Exelixis At Inflection Point ...
08/07/2024 18:15:59

Exelixis reports strong Q2 earnings with adjusted EPS of $0.84, surpassing estimates. The CONTACT-02 trial for mCRPC showed sig...

rbc-capital-reiterates-outperform-on-exelixis-maintains-27-price-target
RBC Capital Reiterates Outperform on Exeli...
08/07/2024 16:17:17

RBC Capital analyst Gregory Renza reiterates Exelixis (NASDAQ:EXEL) with a Outperform and maintains $27 price target.

us-stocks-set-to-extend-gains-despite-mixed-earnings-vix-dips-back-toward-pre-sell-off-levels-analyst-says-pullback-is-a-growth-scare-and-not-calamity
US Stocks Set To Extend Gains Despite Mixe...
08/07/2024 11:45:33

Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to ...

exelixis-sees-2024-total-revenues-1975b-2075b-vs-188b-est
Exelixis Sees 2024 Total Revenues $1.975B-...
08/06/2024 20:46:10

exelixis-q2-2024-adj-eps-084-beats-030-estimate-sales-637178m-beat-465005m-estimate
Exelixis Q2 2024 Adj. EPS $0.84 Beats $0.3...
08/06/2024 20:06:37

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.30 by 180...

wall-street-rebounds-after-selloff-vix-falls-dollar-surges-against-yen-whats-driving-markets-tuesday
Wall Street Rebounds After Selloff, VIX Fa...
08/06/2024 18:29:26

U.S. stock markets saw a strong recovery on Tuesday, with both the S&P 500 and the Nasdaq 100 climbing over 2%, nearly offs...

exelixis-announces-us-fda-accepted-the-supplemental-nda-for-cabozantinib-for-patients-with-advanced-neuroendocrine-tumors
Exelixis Announces U.S. FDA Accepted The S...
08/06/2024 12:38:39

– The FDA assigned a Prescription Drug User Fee Act target action date of April 3, 2025 –– Application is based on results from...

us-stocks-set-to-open-higher-after-mondays-crash-vix-plummets-analyst-says-would-have-worried-if-market-surged-higher-without-correction
US Stocks Set To Open Higher After Monday'...
08/06/2024 11:18:59

Strong sell-off may be viewed as an opportunity to load up beaten-down stocks but traders may seek evidence regarding sustainab...

oppenheimer-maintains-outperform-on-exelixis-maintains-29-price-target
Oppenheimer Maintains Outperform on Exelix...
07/30/2024 16:48:12

Oppenheimer analyst Jay Olson maintains Exelixis (NASDAQ:EXEL) with a Outperform and maintains $29 price target.

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
05/31/2024 17:35:21

over-8m-bet-on-this-health-care-stock-check-out-these-4-stocks-insiders-are-buying
Over $8M Bet On This Health Care Stock? Ch...
05/31/2024 13:26:35

exelixis-settles-with-cipla-to-resolve-two-patent-litigation-grants-cipla-license-to-market-generic-versions-of-cabometyx-on-jan-1-2031-if-approved-by-fda-and-subject-to-conditions-parties-terminate-all-hatch-waxman-litigation-regarding-cabometyx
Exelixis Settles With Cipla To Resolve Two...
05/20/2024 12:17:13

stephens--co-initiates-coverage-on-exelixis-with-equal-weight-rating-announces-price-target-of-23
Stephens & Co. Initiates Coverage On Exeli...
05/14/2024 13:34:20

Stephens & Co. analyst Sudan Loganathan initiates coverage on Exelixis (NASDAQ:EXEL) with a Equal-Weight rating and anno...

macrogenics-gets-downgraded-following-disappointing-prostate-cancer-trial-results-we-were-surprised-by-reported-deaths
MacroGenics Gets Downgraded Following Disa...
05/10/2024 19:08:03

Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.

hc-wainwright--co-reiterates-buy-on-exelixis-maintains-28-price-target
HC Wainwright & Co. Reiterates Buy on Exel...
05/03/2024 20:03:17

HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ:EXEL) with a Buy and maintains $28 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION